Login / Signup

Comprehensive T cell repertoire characterization of non-small cell lung cancer.

Alexandre ReubenJianhua ZhangShin-Heng ChiouRachel M GittelmanJun LiWon-Chul LeeJunya FujimotoCarmen BehrensXiaoke LiuFeng WangKelly QuekChunlin WangFarrah KheradmandRunzhe ChenChi-Wan ChowHeather LinChantale BernatchezAli JalaliXin HuChang-Jiun WuAgda Karina EterovicEdwin Roger Parra CuentesErik YuskoRyan EmersonSharon BenzenoMarissa VignaliXifeng WuYuanqing YeLatasha D LittleCurtis GumbsXizeng MaoXingzhi SongSamantha TippenRebecca L ThorntonTina CasconeAlexandra SnyderJennifer A WargoRoy HerbstStephen G SwisherHumam KadaraCesar MoranNeda KalhorJianhua ZhangPaul ScheetAra A VaporciyanBoris SepesiDon L GibbonsHarlan RobinsPatrick HwuJohn V HeymachPadmanee SharmaJames P AllisonVeera BaladandayuthapaniJiun-Kae Jack LeeMark M DavisIgnacio I WistubaP Andrew FutrealJianjun Zhang
Published in: Nature communications (2020)
Immunotherapy targeting T cells is increasingly utilized to treat solid tumors including non-small cell lung cancer (NSCLC). This requires a better understanding of the T cells in the lungs of patients with NSCLC. Here, we report T cell repertoire analysis in a cohort of 236 early-stage NSCLC patients. T cell repertoire attributes are associated with clinicopathologic features, mutational and immune landscape. A considerable proportion of the most prevalent T cells in tumors are also prevalent in the uninvolved tumor-adjacent lungs and appear specific to shared background mutations or viral infections. Patients with higher T cell repertoire homology between the tumor and uninvolved tumor-adjacent lung, suggesting a less tumor-focused T cell response, exhibit inferior survival. These findings indicate that a concise understanding of antigens and T cells in NSCLC is needed to improve therapeutic efficacy and reduce toxicity with immunotherapy, particularly adoptive T cell therapy.
Keyphrases